Ubamatamab
2023-1062
Phase 2 small_molecule active
Quick answer
Ubamatamab for SMARCB1-Deficient Malignancies is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- SMARCB1-Deficient Malignancies
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active